|
GENERIC
|
Betaxolol HCI 0.25%, 0.5%
|
|
INDICATIONS
|
Reduction of elevated intraocular pressure (IOP)
|
|
MECHANISM OF ACTION
|
Selective B1 receptor blocker
|
|
MICROBIOLOGY
|
The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.
|
|
CONTRAINDICATIONS & WARNINGS
|
Hypersensitivity to any component of this product. BETOPTIC Ophthalmic Solution is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.
|
|
PEDIATRIC USE
|
Safety and effectiveness in pediatric patients have not been established.
|
|
PREGNANCY
|
There are no adequate and well-controlled studies in pregnant women.
|
|
NOTE
|
Betoptic S is the suspension (Shake well before use)
|
